MANAGEMENT OF ESSENTIAL-HYPERTENSION IN PATIENTS WITH DIFFERENT DEGREES OF LEFT-VENTRICULAR HYPERTROPHY - MULTICENTER TRIAL

被引：109

作者：

YURENEV, AP

DYAKONOVA, HG

NOVIKOV, ID

VITOLS, A

PAHL, L

HAYNEMANN, G

WALLRABE, D

TSIFKOVA, R

ROMANOVSKA, L

NIDERLE, P

TSISKARISHVILI, DL

DAVARASHVILI, T

GELOVANI, K

KOCHACHIDZE, T

BALASH, A

机构：

[1] USSR Cardiology Research Center, Academy of Sciences of the USSR, Moscow

[2] Institute of Cardiology of the Latvian Soviet Socialist Republic, Riga

[3] Central Institute of Heart and Circulation Research, Berlin

[4] Institute of Clinical and Experimental Medicine, Prague

[5] Institute of Internal Medicine, Tbilisi

[6] Institute of Cardiology, Tbilisi

[7] Computer Center, Ministry of Health, Budapest

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1992年 / 5卷 / 06期

关键词：

LEFT VENTRICULAR HYPERTROPHY; BETA-BLOCKERS; HYPERTENSION MORBIDITY AND MORTALITY;

D O I：

10.1093/ajh/5.6.182S

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Three hundred and four hypertensive patients with different degrees of left ventricular hypertrophy (LVH) were recruited and followed for 4 years. The patients were randomized into two groups: Group I (150 patients) was treated with a combination of hypotensive drugs including beta-blockers, and group II (154 patients) was treated with the same combination of drugs including diuretics instead of beta-blockers. By the end of the fourth year, 60 endpoints were recorded: 17 strokes, 13 myocardial infarctions, and 30 cases of chronic coronary insufficiency. Mortality was statistically higher in group II (7 of 154 or 5% v 1 of 150 or 1%) (P < .035), but there was no difference between the groups in the incidence of nonfatal endpoints. These data confirm that beta-blockers can reduce mortality associated with the complications presented in hypertensive patients. Increased left ventricular myocardial mass (> 200 g, according to Teichholz' formula) was shown to have prognostic value for the development of complications. In patients with LVMM > 200 g, the probability of fatal complications was higher (P < .007), as was the probability of nonfatal myocardial infarction (P < .01), development of coronary artery disease (P < .02), and all complications (P < .0003). Regression of LVH to < 200 g (according to Teichholz' formula) improved prognosis.

引用

页码：S182 / S189

页数：8

共 37 条

[1]

Casale P.W., Devereux R.B., Milner M., Et al., Value of echo- cardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men, Ann Intern Med, 105, pp. 173-178, (1986)

[2]

Roberts W.C., Frequency of systemic hypertension in various cardiovascular diseases, Am J Cardiol, 60, 6, pp. 1E-8E, (1987)

[3]

Cruickshank J.M., Pennert K., Sorman A.E., Et al., Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives, J Hypertens, 5, pp. 489-498, (1987)

[4]

Hansson L., Aims of treatment of hypertension, J Cardio- Vasc Pharmacol, 10, pp. S51-S54, (1987)

[5]

Ames R.P., Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease, Am J Cardiol, 51, pp. 632-638, (1983)

[6]

Drayer J.I., Echocardiographic detection of LVH. Its usefulness as a prognostic tool in hypertensive patients, Chest, 92, pp. 923-925, (1987)

[7]

Kannel W.B., Gordon T., Offutt D., Left ventricular hypertrophy by electrocardiogram: Prevalence, incidence and mortality in Framingham study, Ann Intern Med, 71, pp. 89-105, (1969)

[8]

Koren M.J., Devereux R.B., Casale P.N., Et al., Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension, Ann Int Med, 114, pp. 345-352, (1991)

[9]

Dunn F.G., Ventura H.O., Messerli F.H., Et al., Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol, Circulation, 76, pp. 254-258, (1987)

[10]

Ferrara L.A., Simone G., Mancini M., Et al., Changes in left ventricular mass during a double blind study with chlorthalidone and slow-release nifedipine, Eur J Clin Pharmacol, 27, pp. 525-529, (1984)

← 1 2 3 4 →